Venetoclax Decreases the Expression of the Spike Protein through Amino Acids Q493 and S494 in SARS-CoV-2
The new coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2) has been reported and spread globally. There is an urgent need to take urgent measures to treat and prevent further infection of this virus. Here, we use virtual drug screening to est...
Main Authors: | Chih-Chieh Chen, Zhi-Jie Zhuang, Chia-Wei Wu, Yi-Ling Tan, Chen-Hsiu Huang, Chia-Yi Hsu, Eing-Mei Tsai, Tsung-Hua Hsieh |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-06-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/11/12/1924 |
Similar Items
-
In Vitro and In Silico Studies for the Identification of Potent Metabolites of Some High-Altitude Medicinal Plants from Nepal Inhibiting SARS-CoV-2 Spike Protein
by: Saroj Basnet, et al.
Published: (2022-12-01) -
Triterpene Derivatives as Potential Inhibitors of the RBD Spike Protein from SARS-CoV-2: An In Silico Approach
by: Mayra Avelar, et al.
Published: (2023-03-01) -
Development of SARS-CoV-2 Inhibitors Using Molecular Docking Study with Different Coronavirus Spike Protein and ACE2
by: Israa Mohamed Shamkh, et al.
Published: (2021-06-01) -
Identifying epitopes for cluster of differentiation and design of new peptides inhibitors against human SARS-CoV-2 spike RBD by an in-silico approach
by: Jihane Akachar, et al.
Published: (2020-12-01) -
Molecular docking between human TMPRSS2 and SARS-CoV-2 spike protein: conformation and intermolecular interactions
by: Mushtaq Hussain, et al.
Published: (2020-09-01)